Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00109941 · ClinicalTrials.gov registry record · Phase 2
Opioid Growth Factor in Treating Patients With Advanced Pancreatic Cancer That Cannot Be Removed By Surgery
A Phase 2 study, sponsored by Milton S. Hershey Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00109941 is a Phase 2 study that has completed, run by Milton S. Hershey Medical Center. The registered enrollment target is 25 participants.
The verdict
NCT00109941, a Phase 2 study, has completed, sponsored by Milton S. Hershey Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
RATIONALE: Opioid growth factor may stop the growth of pancreatic cancer by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well opioid growth factor works in treating patients with advanced pancreatic cancer that cannot be removed by surgery.
Interventions
- BIOLOGICAL opioid growth factor
- BIOLOGICAL metenkephalin, OGF-opioid growth factor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2003-10 |
| Est. Completion | 2009-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00109941
The ClinicalTrials.gov registry entry for NCT00109941 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Milton S. Hershey Medical Center, which has 396 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which opioid growth factor is the first listed.
NCT00109941 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00109941 about?
NCT00109941 is a clinical study titled "Opioid Growth Factor in Treating Patients With Advanced Pancreatic Cancer That Cannot Be Removed By Surgery". RATIONALE: Opioid growth factor may stop the growth of pancreatic cancer by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well opioid growth factor works in treating patients with advanced pancreatic cancer that cannot be removed by surgery.
What is the current status of trial NCT00109941?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2003-10. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00109941?
The interventions under investigation include: opioid growth factor (BIOLOGICAL), metenkephalin, OGF-opioid growth factor (BIOLOGICAL).
Who is sponsoring clinical trial NCT00109941?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.